Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study

BACKGROUND: Reliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic and predictive values of different baseline metabolic pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chardin, David, Paquet, Marie, Schiappa, Renaud, Darcourt, Jacques, Bailleux, Caroline, Poudenx, Michel, Sciazza, Aurélie, Ilie, Marius, Benzaquen, Jonathan, Martin, Nicolas, Otto, Josiane, Humbert, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380842/
https://www.ncbi.nlm.nih.gov/pubmed/32709713
http://dx.doi.org/10.1136/jitc-2020-000645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380842/
https://www.ncbi.nlm.nih.gov/pubmed/32709713
http://dx.doi.org/10.1136/jitc-2020-000645

Ejemplares similares